Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Exciting new therapy for Waldenström’s macroglobulinemia: ibrutinib plus rituximab

Meletios Dimopoulos • 16 Jun 2018
EHA 2018
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Antibodies Ibrutinib Rituximab
iNNOVATE

Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenström’s macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden. Watch Dr Meletios Dimopoulos, of the National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses this groundbreaking study, which could result in a new standard of care for WM.

More from Meletios Dimopoulos

1:07
BelaRd trial: belamaf, lenalidomide, and dex in newly diagnosed MM
Meletios Dimopoulos • 10 Dec 2023
0:49
KdD vs Kd for R/R MM: renal subgroup analysis from CANDOR
Meletios Dimopoulos • 10 Dec 2023
1:19
Results of the PERSEUS trial: D-VRd with D-R maintenance in transplant-eligible newly diagnosed MM
Meletios Dimopoulos • 10 Dec 2023
1:34
iNNOVATE study update: long-term PFS in WM
Meletios Dimopoulos • 5 Dec 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals